Teleflex to Introduce the New Arrow® AC3 Optimus™ Intra-Aortic Balloon Pump & the Product Portfolio from the Recently Acqu...
16 May 2017 - 8:00AM
Business Wire
Teleflex Incorporated (NYSE: TFX), a leading global provider of
medical technologies for critical care, urology and surgery, will
showcase its complex PCI product portfolio recently acquired from
the purchase of Vascular Solutions and the new Arrow® AC3 Optimus™
Intra-Aortic Balloon Pump (IABP) at the EuroPCR being held in
Paris, France on May 16-19, 2017.
With the recent acquisition of Vascular Solutions, Teleflex now
offers a full line of products that give interventional
cardiologists the tools they need to handle routine and complex
cases, resulting in improved outcomes for patients. Cardiologists
worldwide rely on the quality and proven clinical effectiveness of
products, such as the GuideLiner® Catheter Platform, TrapLiner™
Catheter, Turnpike® Catheter, Twin-Pass® Torque Dual Access
Catheter, and R350™ Guidewire.
Teleflex will also introduce the new Arrow® AC3 Optimus IABP.
This device helps a weakened heart pump blood and can deliver IABP
therapy to a broad range of patients, even those not previously
considered candidates for IABP therapy. Clinicians may use the pump
on patients with the most severe arrhythmias or with heart rates as
high as 200 beats per minute.1, 2
The Arrow® AC3 Optimus™ IABP has a third-generation AutoPilot®
Mode, which uses proprietary algorithms to address key clinical
challenges and to simplify the delivery of IABP therapy.3 In
AutoPilot® Mode, the Arrow® AC3 Optimus™ IABP automatically adjusts
timing and triggering parameters, freeing clinicians to focus on
the patient rather than the pump. In addition, the Arrow® AC3
Optimus™ IABP includes several exclusive algorithms, such as WAVE®
Inflation Timing, Deflation Timing Management, and Best Signal
Analysis, which optimize key functions of the IABP to deliver
therapy to the most challenging patients.
About Teleflex Incorporated
Teleflex is a global provider of medical technologies designed
to improve the health and quality of people’s lives. We apply
purpose driven innovation – a relentless pursuit of identifying
unmet clinical needs – to benefit patients and healthcare
providers. Our portfolio is diverse, with solutions in the fields
of vascular and interventional access, surgical, anesthesia,
cardiac care, urology, emergency medicine and respiratory care.
Teleflex employees worldwide are united in the understanding that
what we do every day makes a difference. For more information,
please visit teleflex.com.
Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®,
Pilling®, Rüsch® and Weck® – trusted brands united by a common
sense of purpose.
Forward-Looking Statements
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking
statements. Any forward-looking statements contained herein are
based on our management's current beliefs and expectations, but are
subject to a number of risks, uncertainties and changes in
circumstances, which may cause actual results or company actions to
differ materially from what is expressed or implied by these
statements. These risks and uncertainties are identified and
described in more detail in our filings with the Securities and
Exchange Commission, including our Annual Report on Form 10-K.
Teleflex, the Teleflex logo, Arrow, AC3 Optimus, AutoPilot,
Deknatel, Hudson RCI, LMA, Pilling, R350, Rusch, WAVE, and Weck are
trademarks or registered trademarks of Teleflex Incorporated or its
affiliates, in the U.S. and/or other countries.© 2017 Teleflex
Incorporated. All rights reserved.
References:
- Schreuder J, Castiglioni A, Donelli A,
et al. Automatic intraaortic balloon pump timing using an intra
beat dicrotic notch prediction algorithm. Ann Thorac Surg.
2005;79(3):1017-1022. Study sponsored by Teleflex.
- Donelli A, Jansen JRC, Hoeksel B, et
al. Performance of a real-time dicrotic notch detection and
prediction algorithm in arrhythmic human aortic pressure signals. J
Clin Monit. 2002;17(3-4):181-185. Study sponsored by Teleflex.
- Torracca, L. Overcoming
electro-surgical inference in IABP therapy with the combined use of
AutoPilot and FiberOptix IAB sensor signal. 2007. (Case report,
data on file). Study sponsored by Teleflex.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170515006618/en/
Teleflex IncorporatedJake ElguiczeTreasurer and Vice President,
Investor Relations610-948-2836orMartina Teichmann-ZindlerSenior
Director Marketing Communications International+49
(0)7151-406-538martina.teichmann@teleflex.com
Teleflex (NYSE:TFX)
Historical Stock Chart
From Apr 2024 to May 2024
Teleflex (NYSE:TFX)
Historical Stock Chart
From May 2023 to May 2024